Javascript must be enabled to continue!
Abstract 1561: Detection of colorectal cancer-associated genetic and epigenetic alterations in urine of patients with CRC
View through CrossRef
Abstract
Colorectal cancer (CRC) has been the second leading cause of cancer-related deaths due in part to a low compliance rate (<50%) of the current screening method, an invasive colonoscopy, resulting in failure of detecting cancer early in its curative stages. 20% of CRC cases are only detected once the cancer has spread to a distant site, drastically reducing the 5-year survival rate from 90% to 12%. In order to improve the success of early detection methods of CRC, we have focused on developing non-invasive, multi-biomarker detection assays designed to identify CRC-associated genetic alterations. We have previously demonstrated that urine contains circulation-derived low molecular weight (LMW) DNA (<300 bp), which suggests that LMW urine DNA could be used to detect CRC-associated genetic alterations. Using previously identified stool and serum-based biomarkers for CRC, we have developed a panel of potential CRC markers for early detection for use in a non-invasive urine DNA test. Our panel contains genetic mutations and epigenetic alterations of nine genes: mutations of KRAS codons 12/13 and BRAF V600E and aberrant hypermethylation of VIM, SEPT9, BMP3, NDRG4, CDKN2A, TFPI2, and MGMT. The proof-of-concept of a CRC urine DNA test was demonstrated in a small pilot study investigating mVIM as a biomarker for CRC in matched tissue-urine samples. This led to the development of a PCR-based approach to quantify these markers in a prevalidation study with blinded CRC samples to identify the specificity and sensitivity of these genetic mutations and epigenetic alterations. In a concordant study using this blinded CRC sample set, our panel of markers was used in an amplicon NGS-based study. Results from these two studies will be used to confirm the sensitivity and specificity of each marker for early detection of CRC.
Citation Format: Adam Winfield Clemens, Selena Lin, Surbhi Jain, Ying-Hsiu Su, Wei Song. Detection of colorectal cancer-associated genetic and epigenetic alterations in urine of patients with CRC. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1561. doi:10.1158/1538-7445.AM2015-1561
American Association for Cancer Research (AACR)
Title: Abstract 1561: Detection of colorectal cancer-associated genetic and epigenetic alterations in urine of patients with CRC
Description:
Abstract
Colorectal cancer (CRC) has been the second leading cause of cancer-related deaths due in part to a low compliance rate (<50%) of the current screening method, an invasive colonoscopy, resulting in failure of detecting cancer early in its curative stages.
20% of CRC cases are only detected once the cancer has spread to a distant site, drastically reducing the 5-year survival rate from 90% to 12%.
In order to improve the success of early detection methods of CRC, we have focused on developing non-invasive, multi-biomarker detection assays designed to identify CRC-associated genetic alterations.
We have previously demonstrated that urine contains circulation-derived low molecular weight (LMW) DNA (<300 bp), which suggests that LMW urine DNA could be used to detect CRC-associated genetic alterations.
Using previously identified stool and serum-based biomarkers for CRC, we have developed a panel of potential CRC markers for early detection for use in a non-invasive urine DNA test.
Our panel contains genetic mutations and epigenetic alterations of nine genes: mutations of KRAS codons 12/13 and BRAF V600E and aberrant hypermethylation of VIM, SEPT9, BMP3, NDRG4, CDKN2A, TFPI2, and MGMT.
The proof-of-concept of a CRC urine DNA test was demonstrated in a small pilot study investigating mVIM as a biomarker for CRC in matched tissue-urine samples.
This led to the development of a PCR-based approach to quantify these markers in a prevalidation study with blinded CRC samples to identify the specificity and sensitivity of these genetic mutations and epigenetic alterations.
In a concordant study using this blinded CRC sample set, our panel of markers was used in an amplicon NGS-based study.
Results from these two studies will be used to confirm the sensitivity and specificity of each marker for early detection of CRC.
Citation Format: Adam Winfield Clemens, Selena Lin, Surbhi Jain, Ying-Hsiu Su, Wei Song.
Detection of colorectal cancer-associated genetic and epigenetic alterations in urine of patients with CRC.
[abstract].
In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA.
Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1561.
doi:10.
1158/1538-7445.
AM2015-1561.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Abstract LB121: Endothelial cells mediated paracrine signaling alters immune cell modulators on colorectal cancer cells
Abstract LB121: Endothelial cells mediated paracrine signaling alters immune cell modulators on colorectal cancer cells
Abstract
Background: Metastatic colorectal cancer (mCRC) is the second leading cause of cancer related deaths in the US. Various factors in the tumor microenvironmen...
Alcohol dehydrogenase, iron containing, 1promoter hypermethylation associated with colorectal cancer differentiation
Alcohol dehydrogenase, iron containing, 1promoter hypermethylation associated with colorectal cancer differentiation
Abstract
Background
The aberrant methylation of CpG islands in the promoter is associated with colorectal cancer (CRC) carcinogenesis. In our pre...
Abstract 2089: Epigenetic regulation of sprouty2 in colorectal cancer
Abstract 2089: Epigenetic regulation of sprouty2 in colorectal cancer
Abstract
Background: The specific role of Sprouty-2 in colorectal cancer (CRC) as either a tumor suppressor or an oncogene is unclear. This is further obscured by th...
Label-free quantitative proteomics reveals aberrant expression levels of LRG, C9, FN, A1AT and AGP1 in the plasma of patients with colorectal cancer
Label-free quantitative proteomics reveals aberrant expression levels of LRG, C9, FN, A1AT and AGP1 in the plasma of patients with colorectal cancer
Abstract
Background
Colorectal cancer (CRC) is one of the major causes of cancer-related death worldwide. Although commercial biomarkers of CRC are ...
Abstract 655: Clinicopathological and genetic features of colorectal cancer in Algerian patients
Abstract 655: Clinicopathological and genetic features of colorectal cancer in Algerian patients
Abstract
Background Colorectal carcinoma is the third most common form of cancer worldwide. It is the second most common cancer in men and women in Algeria.The aim o...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

